Niraparib

PRIMA/ENGOT-OV26/COG-3012



Niraparib PRIMA/ENGOT-OV26/COG-3012	Niraparib PRIMA/ENGOT-OV26/COG-3012
PRELIMINARY SCORE	FINAL SCORE
CURATIVE	CURATIVE
	Overall Survival / Disease-Free Survival / Pathological Complete Response
NON-CURATIVE	NON-CURATIVE
PFS	NON-CURATIVE
ADJUSTMENTS	Overall Survival
Quality of life	3
	Progression-Free Survival
	Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate
Serious and disabling adverse effects	
	Overall Response Rate / Duration of Response
	Overall Survival / Disease-Free Survival / Pathological Complete Response
Other adjustments	INFORMATION
	Tumour type: Gynaecological Malignancies Therapeutic Indication: Maintenance treatment for high grade ovarian, fallopian tube or peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based ChT Experimental Arm: Niraparib Control Arm: Placebo

